SARS2-38 binds a conserved RBD epitope near the receptor-binding motif, enabling neutralization of variants carrying escape mutations that defeat other antibodies. Most neutralizing antibodies target mutable RBD or NTD regions, allowing variants to escape; SARS2-38's conserved epitope approach addresses this evolutionary pressure.
News-Medical.net
· Apr 29, 2021
· health
· 3 min de leitura
Medium
Apuração: Caracterizado
Researchers identify monoclonal antibody effective against SARS-CoV-2 variants
◉
Health & Medicine
8412 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
US researchers develop broadly neutralizing monoclonal antibody (SARS2-38) effective against SARS-CoV-2 variants, offering potential therapeutic advancement in pandemic response.
Escalation Risk
low
Confidence
HIGH
United States
Global (pandemic-affected countries)
European Union
Asia-Pacific
Scientific advancement in US biomedical research strengthens American soft power and pharmaceutical leadership. Potential therapeutic monopoly if patented and commercialized could shift global health dependency dynamics, particularly affecting lower-income nations' access to treatments.
Similar to polio vaccine development (1950s) where US scientific breakthroughs established global health influence and shaped international medical policy frameworks.
Lente Econômica
📈
Discovery of broadly neutralizing monoclonal antibody (SARS2-38) effective against SARS-CoV-2 variants could expand therapeutic options, supporting biotech/pharma growth and reducing pandemic-related economic disruptions.
Market Signal
bullish
Confidence
MED
Biotechnology/Pharmaceuticals
Healthcare/Medical devices
Diagnostics
Hospital/Clinical services
Vaccine development
Consumers gain access to additional treatment options for COVID-19 variants, potentially reducing hospitalization rates, mortality, and healthcare costs. May lower out-of-pocket medical expenses and reduce lost productivity from illness.
Likely to accelerate FDA review pathways for monoclonal antibody therapeutics; may influence public health strategies to balance vaccines and treatments; could affect government procurement budgets for pandemic response; may inform future pandemic preparedness frameworks.